Camille Abboud, MD
Medical Oncology · Saint Louis, MONPI 1316965320
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,010 of the $69,844 with a category attached, or 60.1%. 25 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 48.9% of the total. Reporting peaked in 2019 at $49,306 and has fallen 97.5% since, to $1,213 in 2025. Among medical oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 85 payments — averaging $821.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$34K
- Pfizer$8K
- Dova Pharmaceuticals$7K
- Novartis$5K
- Blueprint Medicines Corporation$4K
- AstraZeneca$3K
- plus $9K from 19 others
Across 62 payments — averaging $110,137 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$5.7M
- Pfizer$917K
- Gilead$131K
- AbbVie$34K
- AstraZeneca$25K
What the payments were for
- Consulting fees$18,65227%
- Speaking & faculty fees$42,01060%
- Travel & lodging$5,7458%
- Food & beverage$3,1254%
- Education$3120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 28 | $34,155 |
| Pfizer | 11 | $8,471 |
| Dova Pharmaceuticals | 2 | $6,640 |
| Novartis | 10 | $4,781 |
| Blueprint Medicines Corporation | 1 | $3,960 |
| AstraZeneca | 1 | $3,083 |
| Bristol Myers Squibb | 6 | $3,009 |
| E.r. Squibb & Sons, L.L.C. | 4 | $2,516 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Beigene, Ltd. | 1 | $525 |
| Beigene USA, Inc. | 1 | $525 |
| Sanofi | 2 | $278 |
| Gilead | 3 | $261 |
| Astellas Pharma US Inc | 2 | $198 |
| Stemline Therapeutics Inc. | 2 | $184 |
| Incyte Corporation | 1 | $123 |
| Johnson & Johnson | 1 | $122 |
| ADC Therapeutics America, Inc. | 1 | $110 |
| Genmab U.S., Inc. | 1 | $92 |
| Karyopharm Therapeutics Inc. | 1 | $69 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
| Sobi, Inc | 1 | $22 |
| AbbVie | 1 | $18 |
| Novo Nordisk | 1 | $14 |
| Acrotech Biopharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$69,844 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 196 | $2,758,668 |
| RevlimidLenalidomide | 82 | $1,463,153 |
| JakafiRuxolitinib Phosphate | 49 | $850,721 |
| CalquenceAcalabrutinib Maleate | 45 | $685,082 |
| ScemblixAsciminib Hydrochloride | 27 | $564,617 |
| OjjaaraMomelotinib Dihydrochloride | 20 | $517,384 |
| ImbruvicaIbrutinib | 29 | $436,558 |
| Lenalidomide | 28 | $374,334 |
| VenclextaVenetoclax | 57 | $364,395 |
| IclusigPonatinib Hcl | 19 | $294,585 |
| RezurockBelumosudil Mesylate | 13 | $231,644 |
| BosulifBosutinib | 15 | $211,682 |
| SprycelDasatinib | 13 | $169,027 |
| PomalystPomalidomide | 14 | $166,679 |
| Imatinib Mesylate | 49 | $157,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $525 | $2,758,668196 claims |
| Bristol Myers SquibbRevlimid | $3,009 | $1,463,15382 claims |
| Incyte CorporationJakafi | $123 | $850,72149 claims |
| AstraZenecaCalquence | $3,083 | $685,08245 claims |
| NovartisScemblix | $4,781 | $564,61727 claims |
| AbbVieVenclexta | $18 | $364,39557 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel, Pomalyst | $2,516 | $335,70527 claims |
| PfizerBosulif, Eliquis | $8,471 | $225,95137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 144 medical oncology providers in Missouri.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
- Maurice WillisSaint Louis$101K
- Moh'd KhushmanSaint Louis$84K
- Bruce RothSaint Louis$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.